MCID: VCC001
MIFTS: 49

Vaccinia

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Vaccinia

MalaCards integrated aliases for Vaccinia:

Name: Vaccinia 12 43 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3298
MeSH 43 D014615
UMLS 71 C0042214

Summaries for Vaccinia

Disease Ontology : 12 A viral infectious disease that results in infection, located in skin, has material basis in Vaccinia virus, which is used as a live vaccine against smallpox. The virus is transmitted by contact with the vaccination site before it has healed, or transmitted by fomites that have been contaminated with live virus from the vaccination site. The infection has symptom rash, has symptom fever, and has symptom body aches.

MalaCards based summary : Vaccinia is related to measles and newcastle disease, and has symptoms including fever, rash and body aches. An important gene associated with Vaccinia is VRK1 (VRK Serine/Threonine Kinase 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Sorafenib and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and prostate, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It... more...

Related Diseases for Vaccinia

Diseases related to Vaccinia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 368)
# Related Disease Score Top Affiliating Genes
1 measles 31.0 IRF7 IRF3 IL2 EIF2AK2
2 newcastle disease 30.9 IRF7 IRF3 EIF2AK2
3 stomatitis 30.9 IL2 EIF2AK2 CSF2
4 viral infectious disease 30.5 IRF7 IRF3 IL2 EIF2AK2
5 cowpox 11.7
6 smallpox 11.1
7 variola major 11.1
8 obsolete: small pox 10.9
9 herpes simplex 10.7
10 human immunodeficiency virus type 1 10.6
11 rabies 10.6
12 monkeypox 10.6
13 encephalitis 10.6
14 dermatitis 10.5
15 severe combined immunodeficiency 10.5
16 immune deficiency disease 10.5
17 chickenpox 10.4
18 dermatitis, atopic 10.4
19 melanoma 10.4
20 influenza 10.4
21 cytokine deficiency 10.4
22 allergic hypersensitivity disease 10.4
23 avian influenza 10.4
24 colon adenocarcinoma 10.3
25 molluscum contagiosum 10.3
26 hepatitis c virus 10.3
27 microphthalmia with limb anomalies 10.3 IRF7 IRF3 EIF2AK2
28 fibroma 10.3
29 lymphocytic choriomeningitis 10.3
30 severe acute respiratory syndrome 10.3
31 glioma 10.3
32 glial tumor 10.3
33 keratitis, hereditary 10.3
34 polykaryocytosis inducer 10.3
35 pancreatic cancer 10.3
36 japanese encephalitis 10.3
37 skin disease 10.3
38 poliomyelitis 10.3
39 triiodothyronine receptor auxiliary protein 10.2
40 hepatitis b 10.2
41 erythroleukemia, familial 10.2
42 kala-azar 1 10.2
43 leishmaniasis 10.2
44 colorectal cancer 10.2
45 squamous cell papilloma 10.2
46 papilloma 10.2
47 exanthem 10.2
48 hepatitis c 10.2
49 hepatocellular carcinoma 10.2
50 hepatitis a 10.2

Graphical network of the top 20 diseases related to Vaccinia:



Diseases related to Vaccinia

Symptoms & Phenotypes for Vaccinia

Symptoms:

12
  • fever
  • rash
  • body aches

MGI Mouse Phenotypes related to Vaccinia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.77 AZI2 BTRC CSF2 DUSP3 EIF2AK2 EPS15
2 immune system MP:0005387 9.44 AZI2 BTRC CSF2 DUSP3 EIF2AK2 EPS15

Drugs & Therapeutics for Vaccinia

Drugs for Vaccinia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
2
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
3
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
4
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
5
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
6
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
7
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
8
Pemetrexed Approved, Investigational Phase 2, Phase 3 150399-23-8, 137281-23-3 446556 60843
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
10 Iron-Dextran Complex Phase 3
11 Immunologic Factors Phase 2, Phase 3
12 Angiogenesis Inhibitors Phase 2, Phase 3
13 Protein Kinase Inhibitors Phase 2, Phase 3
14 Anti-Infective Agents Phase 2, Phase 3
15 Antiviral Agents Phase 2, Phase 3
16 Antineoplastic Agents, Immunological Phase 2, Phase 3
17 Immunosuppressive Agents Phase 2, Phase 3
18 Antimetabolites Phase 2, Phase 3
19 Albumin-Bound Paclitaxel Phase 2, Phase 3
20 Antimitotic Agents Phase 2, Phase 3
21 Vitamin B Complex Phase 2, Phase 3
22 Folic Acid Antagonists Phase 2, Phase 3
23 Vitamin B9 Phase 2, Phase 3
24 Folate Phase 2, Phase 3
25
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
26
Oxaliplatin Approved, Investigational Phase 1, Phase 2 61825-94-3 5310940 9887054 6857599 43805
27
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
28
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
29
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
30
Phenol Approved, Experimental Phase 2 108-95-2 996
31
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
32
Bicalutamide Approved Phase 2 90357-06-5 56069 2375
33
Goserelin Approved Phase 2 65807-02-5, 1233494-97-7 47725 5311128
34
tannic acid Approved Phase 1, Phase 2 1401-55-4
35
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
36
Nilutamide Approved, Investigational Phase 2 63612-50-0 4493
37
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 772 46507594
38
Coal tar Approved Phase 1, Phase 2 8007-45-2
39
Testosterone Approved, Experimental, Investigational Phase 2 58-22-0, 481-30-1 6013 10204
40
Flutamide Approved, Investigational Phase 2 13311-84-7 3397
41
Lenograstim Approved, Investigational Phase 2 135968-09-1
42
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
43
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
44
acetic acid Approved Phase 2 64-19-7 176
45
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
46
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
47
Metronidazole Approved Phase 2 443-48-1 4173
48
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
49
nivolumab Approved Phase 2 946414-94-4
50
Darunavir Approved Phase 2 635728-49-3, 206361-99-1 213039

Interventional clinical trials:

(show top 50) (show all 265)
# Name Status NCT ID Phase Drugs
1 A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus Completed NCT03472014 Phase 4
2 Phase 4 Study of Speeda® Rabies Vaccinia That Use for Protection the Crowd Bitten by Animals to Three-level Completed NCT01827917 Phase 4
3 Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Recruiting NCT02443623 Phase 4
4 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Completed NCT01158157 Phase 3
5 A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects Completed NCT01144637 Phase 3
6 A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects Completed NCT01913353 Phase 3
7 The Clinical Study of Analgecine for the Treatment of Neuropathic Pain Completed NCT02633618 Phase 3
8 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
9 A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate A Range of Dose Levels of a Heterologous Prime‐Boost Regimen of Ad26.ZEBOV and MVA‐BN®‐Filo in Healthy Adult Subjects Completed NCT02543567 Phase 3
10 A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of a Heterologous Prime‐Boost Regimen Using Three Different Batches of Ad26.ZEBOV and a Single Batch of MVA‐BN®‐Filo in Healthy Adult Subjects Completed NCT02543268 Phase 3
11 A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola Completed NCT02509494 Phase 3
12 An Open-Label Prospective Cohort Study of IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
13 Evaluation of a Heterologous, Two-dose Preventive Ebola Vaccine for Effectiveness and Safety in the Democratic Republic of the Congo Recruiting NCT04152486 Phase 3
14 A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy Active, not recruiting NCT02562755 Phase 3 Sorafenib
15 A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Active, not recruiting NCT03699124 Phase 3
16 A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Active, not recruiting NCT02661464 Phase 3
17 A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Terminated NCT01383148 Phase 2, Phase 3 placebo
18 A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers Unknown status NCT00103584 Phase 1, Phase 2
19 INTRALESIONAL IMMUNOTHERAPY WITH A VACCINIA/GM-CSF RECOMBINANT VIRUS IN PATIENTS WITH METASTATIC MELANOMA Unknown status NCT00002817 Phase 1, Phase 2
20 A Randomised Double-blind, Placebo-controlled Phase I/IIa Trial to Investigate the Effect of Depletion of Serum Amyloid P Component (SAP) on the Immune Response to DNA Vaccination in Healthy Male Volunteers Unknown status NCT02425241 Phase 1, Phase 2 CPHPC
21 A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
22 A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma. Completed NCT01394939 Phase 1, Phase 2 Irinotecan
23 Phase IIa Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) Completed NCT01705223 Phase 2
24 A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
25 Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31] Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
26 Phase I/II Study of Intraperitoneal Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Peritoneal Carcinomatosis Completed NCT01443260 Phase 1, Phase 2
27 A Phase 2 Open-Label Pilot Safety Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by IV Infusion Followed by Intratumoral Injection Prior to Standard Sorafenib Treatment in Patients With Unresectable Primary Hepatocellular Carcinoma Completed NCT01171651 Phase 2 JX-594 followed by sorafenib
28 Active Specific Intranodal Immunotherapy With a Recombinant Vaccinia Virus Expressing Three Melanoma Associated Epitopes and Two Costimulatory Molecules, Followed by Immunization With Synthetic Melanoma Associated Epitopes. A Phase I/II Trial in Patients With Stages IIb to IV Melanoma Completed NCT00116597 Phase 1, Phase 2
29 A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients With Advanced Hepatocellular Carcinoma (HCC) Completed NCT01636284 Phase 2
30 A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults. Completed NCT00050518 Phase 2
31 A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment Completed NCT01387555 Phase 2
32 Treatment Of Patients With Metastatic Melanoma Using Recombinant Vaccinia And Fowlpox Viruses Encoding The Tyrosine Antigen In Combination With Interleukin-2 Completed NCT00054535 Phase 2
33 Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer Completed NCT00003871 Phase 2
34 A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma Completed NCT00429312 Phase 1, Phase 2
35 ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax® Immunization to Assess Effects of MVA Vaccination on Dryvax® Takes Completed NCT00133575 Phase 1, Phase 2
36 A Comparison of Dressing Preparations for Smallpox Vaccination Sites With a Focus Upon the Risk of Secondary Transmission of Vaccinia Virus Completed NCT00063856 Phase 1, Phase 2
37 A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Various Concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-naive Adults Completed NCT00038987 Phase 1, Phase 2
38 A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl. Completed NCT00316589 Phase 2
39 A Combined Phase 1/2a, Exploratory Study of a Therapeutic Vaccine Using an Adenovirus Type 26 Vector Prime and Modified Vaccinia Ankara Boost Combination With Mosaic Inserts in HIV-1 Infected Adults Who Initiated Antiretroviral Treatment During Acute HIV Infection Completed NCT02919306 Phase 1, Phase 2 Placebo
40 A Multicenter, Double-Blind, Randomized Dose-Response Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults Completed NCT00026611 Phase 2
41 Comparison of Safety and Immunogenicity of a High Dose (5 x 10^8 TCID50) and a Standard Dose (1 x 10^8 TCID50) of IMVAMUNE® in Healthy Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
42 A Multicenter, Double Blind, Randomized Dose-response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults Completed NCT00050505 Phase 2
43 Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals Completed NCT00914732 Phase 2
44 Immunization of Patients With Metastatic Melanoma Using Recombinant Fowlpox and Vaccinia Viruses Encoding the Tyrosinase Antigen Completed NCT00019734 Phase 2
45 A Pilot Study Of Sequential Vaccinations With Recombinant Vaccinia-CEA(6D)-TRICOM, And Recombinant Fowlpox-CEA(6D)-TRICOM (B7.1/ICIAM-1/LFA-3) With Sargramostim (GM-CSF), In Conjunction With Standard Adjuvant Chemotherapy In High Risk Breast Cancer Patients Status Post Surgery With 4+ Or More Lymph Nodes And CEA Expressing Tumors Completed NCT00052351 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
46 A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer Completed NCT00108732 Phase 2 Bicalutamide;Goserelin Acetate
47 A Randomized, Placebo-Controlled, Dosage-Escalating Phase 2A Study, Double-Blinded With Respect to Assignment to Either Vaccine or Placebo, to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Administered Intramuscularly Followed by an MVA HIV-1 Vaccine Administered at Three Different Dosage Levels and by Three Different Routes to HIV-Uninfected, Healthy, Volunteers. Completed NCT01371175 Phase 2
48 The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination Completed NCT00053482 Phase 2
49 A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
50 Efficacy Study of ChAd63MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection. Completed NCT01666925 Phase 2

Search NIH Clinical Center for Vaccinia

Cochrane evidence based reviews: vaccinia

Genetic Tests for Vaccinia

Anatomical Context for Vaccinia

The Foundational Model of Anatomy Ontology organs/tissues related to Vaccinia:

19
Skin

MalaCards organs/tissues related to Vaccinia:

40
T Cells, Prostate, Skin, Lung, Testes, Breast, Liver

Publications for Vaccinia

Articles related to Vaccinia:

(show top 50) (show all 13330)
# Title Authors PMID Year
1
Selective reconstitution of IFN‑γ gene function in Ncr1+ NK cells is sufficient to control systemic vaccinia virus infection. 61
32023327 2020
2
Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells. 61
32019881 2020
3
The DI-DII linker of human parainfluenza virus type 3 fusion protein is critical for the virus. 61
31768710 2020
4
Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice. 61
32016547 2020
5
Evidence of vaccinia dissemination despite lack of major reaction following smallpox vaccination. 61
31899026 2020
6
Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma. 61
32019860 2020
7
Immunogenicity of HIV-1 Vaccines Expressing Chimeric Envelope Glycoproteins on the Surface of Pr55 Gag Virus-Like Particles. 61
32013223 2020
8
Lack of B Lymphocytes Enhances CD8 T Cell-Mediated Resistance against Respiratory Viral Infection but Compromises Memory Cell Formation. 61
31723023 2020
9
Vaccinia Virus Glycoproteins A33, A34, and B5 Form a Complex for Efficient Endoplasmic Reticulum to trans-Golgi Network Transport. 61
31941777 2020
10
Prediction of cancer neoepitopes needs new rules. 61
31952902 2020
11
Poxviruses diagnosed in cattle from Distrito Federal, Brazil (2015-2018). 61
31971341 2020
12
Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. 61
31941828 2020
13
Bacterial Artificial Chromosome-Based Lambda Red Recombination with the I-SceI Homing Endonuclease for Genetic Alteration of MERS-CoV. 61
31883087 2020
14
Perfusion Control for High Cell Density Cultivation and Viral Vaccine Production. 61
31858467 2020
15
Suppressors of Cytokine Signaling and Protein Inhibitors of Activated Signal Transducer and Activator of Transcriptions As Therapeutic Targets in Flavivirus Infections. 61
31436502 2020
16
Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara. 61
31708178 2020
17
Cytoplasmic factories, virus assembly, and DNA replication kinetics collectively constrain the formation of poxvirus recombinants. 61
31945138 2020
18
High risk genotypes for schizophrenia may have been adaptive in the context of smallpox. 61
31935637 2020
19
A Virus-Infected, Reprogrammed Somatic Cell-Derived Tumor Cell (VIReST) Vaccination Regime Can Prevent Initiation and Progression of Pancreatic Cancer. 61
31767564 2020
20
Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes. 61
31401821 2020
21
Vaccinia Virus Vectors Targeting Peptides for MHC Class II Presentation to CD4+ T Cells. 61
31896555 2020
22
Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-titer HBV Carrier Mice. 61
32001321 2020
23
Deletion of multiple genes induces virulence reduction of vaccinia virus Tiantan strain. 61
31707001 2020
24
Evaluation of modified Vaccinia Ankara-based vaccines against foot-and-mouth disease serotype A24 in cattle. 61
31718901 2020
25
The membrane binding and deformation property of vaccinia virus K1 ankyrin repeat domain protein. 61
31976592 2020
26
Target Therapy With Vaccinia Virus Harboring IL-24 For Human Breast Cancer. 61
31956348 2020
27
Engineering and Characterization of Oncolytic Vaccinia Virus Expressing Truncated Herpes Simplex Virus Thymidine Kinase. 61
31963415 2020
28
Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria. 61
31740525 2020
29
Molecular and genomic characterization of a novel equine molluscum contagiosum-like virus. 61
31922947 2020
30
Unique IL-13Rα2/STAT3 mediated IL-13 regulation detected in lung conventional dendritic cells, 24 h post viral vector vaccination. 61
31974500 2020
31
Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. 61
31969562 2020
32
RIP1 kinase activity is critical for skin inflammation but not for viral propagation. 61
31985117 2020
33
A Deleted Deletion Site in a New Vector Strain and Exceptional Genomic Stability of Plaque-Purified Modified Vaccinia Ankara (MVA). 61
31833037 2019
34
Loss of Pre-Existing Immunological Memory among HIV Infected Women Despite Immune Reconstitution with Antiretroviral Therapy. 61
31867597 2019
35
Recombinant Modified Vaccinia Virus Ankara (MVA) Vaccines Efficiently Protect Cockatiels Against Parrot Bornavirus Infection and Proventricular Dilatation Disease. 61
31817690 2019
36
Induction of an Alternative mRNA 5' Leader Enhances Translation of the Ciliopathy Gene Inpp5e and Resistance to Oncolytic Virus Infection. 61
31851930 2019
37
Identification of a homozygous VRK1 mutation in two patients with adult-onset distal hereditary motor neuropathy. 61
31837156 2019
38
Common vole (Microtus arvalis) and bank vole (Myodes glareolus) derived permanent cell lines differ in their susceptibility and replication kinetics of animal and zoonotic viruses. 61
31513859 2019
39
Seroprevalence and Risk Factors Possibly Associated with Emerging Zoonotic Vaccinia Virus in a Farming Community, Colombia. 61
31743085 2019
40
An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design. 61
31817622 2019
41
Correction for Chiuppesi et al., "Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Responses against Human Cytomegalovirus in Mice". 61
31723009 2019
42
A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice. 61
31878180 2019
43
Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. 61
31876334 2019
44
Identification of Vaccinia-H1 Related Phosphatase as an Anticancer Target for 1,2,3,4,6-O-Pentagalloylglucose. 61
31797547 2019
45
Ras-PI3K pathway promotes osteosarcoma progression via regulating VRK1-mediated H2A phosphorylation at threonine 120. 61
31810390 2019
46
Vaccinia virus expressing IL-37 promotes antitumor immune responses in hepatocellular carcinoma. 61
31710117 2019
47
Analysis of MHC Class I Processing Pathways That Generate a Response to Vaccinia Virus Late Proteins. 61
31791977 2019
48
Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models. 61
31142183 2019
49
Structural Basis of Poxvirus Transcription: Transcribing and Capping Vaccinia Complexes. 61
31835031 2019
50
Structural Basis of Poxvirus Transcription: Vaccinia RNA Polymerase Complexes. 61
31835032 2019

Variations for Vaccinia

Expression for Vaccinia

Search GEO for disease gene expression data for Vaccinia.

Pathways for Vaccinia

Pathways related to Vaccinia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 VRK3 TANK NLRP1 IRF7 IRF3 IL2
2
Show member pathways
13.13 IRF7 IRF3 IL2 EIF2AK2 CUL1 CSF2
3
Show member pathways
12.53 IRF7 IRF3 EIF2AK2 CUL1 CSF2 BTRC
4
Show member pathways
12.5 TBKBP1 TANK IRF7 IRF3 AZI2
5 12.13 IRF3 CUL1 CSF2 BTRC
6
Show member pathways
12.01 TANK IRF7 CUL1 BTRC
7 11.93 TANK NLRP1 IRF7 IRF3
8 11.61 TBKBP1 TANK NLRP1 IRF7 IRF3 IL2
9
Show member pathways
10.85 VRK2 VRK1 BANF1
10
Show member pathways
10.49 IRF7 IRF3 EIF2AK2

GO Terms for Vaccinia

Cellular components related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.8 VRK3 VRK2 VRK1 TANK NLRP1 ITSN1
2 cytosol GO:0005829 9.44 WASHC2C VRK1 TANK NLRP1 ITSN1 IRF7

Biological processes related to Vaccinia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.93 NLRP1 IRF7 IRF3 IL2 EIF2AK2
2 innate immune response GO:0045087 9.89 TBKBP1 NLRP1 IRF7 IRF3 EIF2AK2
3 response to virus GO:0009615 9.69 IRF7 EIF2AK2 BANF1
4 positive regulation of kinase activity GO:0033674 9.52 ITSN1 IL2
5 dendritic cell differentiation GO:0097028 9.48 CSF2 AZI2
6 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.46 IRF7 IRF3
7 viral process GO:0016032 9.44 VRK2 TBKBP1 TANK NLRP1 ITSN1 IRF7
8 regulation of type I interferon production GO:0032479 9.43 IRF7 IRF3
9 positive regulation of interferon-alpha production GO:0032727 9.4 IRF7 IRF3
10 mitotic nuclear envelope reassembly GO:0007084 9.37 VRK1 BANF1
11 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.33 TANK IRF7 IRF3
12 MDA-5 signaling pathway GO:0039530 9.32 IRF7 IRF3
13 interferon-alpha production GO:0032607 9.26 IRF7 AZI2
14 type I interferon biosynthetic process GO:0045351 8.96 IRF7 IRF3

Molecular functions related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 WASHC2C VRK3 VRK2 VRK1 TBKBP1 TANK
2 kinase activator activity GO:0019209 8.96 ITSN1 IL2

Sources for Vaccinia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....